Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $6.8 million.

  • Praxis Precision Medicines' Cash from Financing Activities rose 370.47% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.4 million, marking a year-over-year decrease of 49.73%. This contributed to the annual value of $514.3 million for FY2024, which is 459.83% up from last year.
  • Latest data reveals that Praxis Precision Medicines reported Cash from Financing Activities of $6.8 million as of Q3 2025, which was down 76.40% from $28.6 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year Cash from Financing Activities high stood at $216.4 million for Q2 2024, and its period low was $504,000 during Q2 2022.
  • In the last 3 years, Praxis Precision Medicines' Cash from Financing Activities had a median value of $41.4 million in 2025 and averaged $69.6 million.
  • As far as peak fluctuations go, Praxis Precision Medicines' Cash from Financing Activities skyrocketed by 13,724.40% in 2023, and later slumped by 86.77% in 2025.
  • Praxis Precision Medicines' Cash from Financing Activities (Quarterly) stood at $5.4 million in 2022, then declined by 23.41% to $4.1 million in 2023, then skyrocketed by 2,657.32% to $113.8 million in 2024, then surged by 370.47% to $6.8 million in 2025.
  • Its Cash from Financing Activities stands at $6.8 million for Q3 2025, versus $28.6 million for Q2 2025 and $54.3 million for Q1 2025.